4//SEC Filing
Driggs Alex 4
Accession 0001171843-18-001099
CIK 0001365216other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 4:41 PM ET
Size
12.0 KB
Accession
0001171843-18-001099
Insider Transaction Report
Form 4
Driggs Alex
General Counsel & Corp. Sec.
Transactions
- Disposition to Issuer
Common Stock, Class A
2018-02-13$18.00/sh−6,084$109,512→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2018-02-13$4.20/sh−24,150$101,430→ 0 totalExercise: $13.80Exp: 2026-03-02→ Common Stock (24,150 underlying) - Disposition to Issuer
Stock Option (right to buy)
2018-02-13$1.96/sh−25,600$50,176→ 0 totalExercise: $16.04Exp: 2025-05-18→ Common Stock (25,600 underlying) - Disposition to Issuer
Stock Option (right to buy)
2018-02-13$6.15/sh−11,068$68,068→ 0 totalExercise: $11.85Exp: 2027-03-02→ Common Stock (11,068 underlying)
Footnotes (2)
- [F1]This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement").
- [F2]This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Documents
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeother
Related Parties
1- filerCIK 0001708997
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 4:41 PM ET
- Size
- 12.0 KB